Insider Trading Alert - FRME, KND And UEPS Traded By Insiders

Yesterday, Aug. 31, 2015, 70 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $889.92 to $16,133,353.20.

Highlighted Stocks Traded by Insiders:

First Merchants (FRME) - FREE Research Report

Becher Michael R, who is Director at First Merchants, bought 100 shares at $25.79 on Aug. 31, 2015. Following this transaction, the Director owned 6,204 shares meaning that the stake was boosted by 1.64% with the 100-share transaction.

The shares most recently traded at $25.59, down $0.20, or 0.78% since the insider transaction. Historical insider transactions for First Merchants go as follows:

  • 4-Week # shares bought: 83
  • 4-Week # shares sold: 1,600
  • 12-Week # shares bought: 230
  • 12-Week # shares sold: 1,600
  • 24-Week # shares bought: 584
  • 24-Week # shares sold: 1,600

The average volume for First Merchants has been 145,900 shares per day over the past 30 days. First Merchants has a market cap of $981.1 million and is part of the financial sector and banking industry. Shares are up 14.37% year-to-date as of the close of trading on Monday.

First Merchants Corporation operates as the financial holding company for First Merchants Bank, National Association that provides community banking services. The stock currently has a dividend yield of 1.7%. The company has a P/E ratio of 14.7. Currently, there is 1 analyst who rates First Merchants a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRME - FREE

TheStreet Quant Ratings rates First Merchants as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full First Merchants Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Kindred Healthcare (KND) - FREE Research Report

Breier Benjamin A, who is President & CEO at Kindred Healthcare, sold 5,400 shares at $20.57 on Aug. 31, 2015. Following this transaction, the President & CEO owned 542,440 shares meaning that the stake was reduced by 0.99% with the 5,400-share transaction.

The shares most recently traded at $19.78, down $0.79, or 4.01% since the insider transaction. Historical insider transactions for Kindred Healthcare go as follows:

  • 4-Week # shares sold: 10,135
  • 12-Week # shares sold: 20,935
  • 24-Week # shares bought: 8,000
  • 24-Week # shares sold: 31,735

The average volume for Kindred Healthcare has been 785,700 shares per day over the past 30 days. Kindred Healthcare has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 10.45% year-to-date as of the close of trading on Monday.

Kindred Healthcare, Inc. provides healthcare services in the United States. It operates in four divisions: Hospital, Nursing Center, Rehabilitation, and Care Management. The stock currently has a dividend yield of 2.33%. Currently, there are 3 analysts who rate Kindred Healthcare a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KND - FREE

TheStreet Quant Ratings rates Kindred Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, poor profit margins and generally higher debt management risk. Get the full Kindred Healthcare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Net 1 Ueps Technologies (UEPS) - FREE Research Report

Seabrooke Christopher Stefan, who is Director at Net 1 Ueps Technologies, sold 1,452 shares at $20.59 on Aug. 31, 2015. Following this transaction, the Director owned 19,633 shares meaning that the stake was reduced by 6.89% with the 1,452-share transaction.

Oh Phil-Hyun, who is President of KSNET at Net 1 Ueps Technologies, sold 927 shares at $20.59 on Aug. 31, 2015. Following this transaction, the President of KSNET owned 19,972 shares meaning that the stake was reduced by 4.44% with the 927-share transaction.

The shares most recently traded at $19.98, down $0.61, or 3.05% since the insider transaction. Historical insider transactions for Net 1 Ueps Technologies go as follows:

  • 4-Week # shares sold: 46,734
  • 12-Week # shares sold: 46,734
  • 24-Week # shares sold: 46,734

The average volume for Net 1 Ueps Technologies has been 317,500 shares per day over the past 30 days. Net 1 Ueps Technologies has a market cap of $970.0 million and is part of the services sector and diversified services industry. Shares are up 80.61% year-to-date as of the close of trading on Monday.

Net 1 UEPS Technologies, Inc. provides payment solutions and transaction processing services for various industries in South Africa, South Korea, and internationally. The company has a P/E ratio of 10.3. Currently, there is 1 analyst who rates Net 1 Ueps Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UEPS - FREE

TheStreet Quant Ratings rates Net 1 Ueps Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Net 1 Ueps Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Stocks Slide, Dollar Weakens as Trade, Trump and Tariffs Hold Down Sentiment

Stocks Slide, Dollar Weakens as Trade, Trump and Tariffs Hold Down Sentiment

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook